New Bill to Address Prescription Drug Shortages

We’ve all spent time looking at the expiration date labels in our fridge and pantry. Sometimes it's apparent that the food in question has gone bad, but sometimes it isn’t. And sometimes the product is fine past the date on the label. The same can be true for prescription drugs. That is the reason that U.S. Senators Susan Collins (R-ME) and Ben Cardin (D-MD) have introduced the Drug Shortages Shelf-Life Extension Act, a bipartisan bill that would direct the U.S. Food and Drug Administration (FDA) to extend the shelf life of prescription drugs in scarce supply.

New Bill to Address Prescription Drug Shortages

FDA Logo

Reporting by Jon Terry
January 20, 2022

Washington, D.C. – U.S. Senators Susan Collins (R-ME) and Ben Cardin (D-MD) introduced the Drug Shortages Shelf-Life Extension Act, a bipartisan bill that would direct the U.S. Food and Drug Administration (FDA) to extend the shelf life of prescription drugs in scarce supply. According to the FDA, amending the expiration date of some prescription drugs may alleviate the shortages that the United States currently is facing.

Continue Reading

Here’s wishing everyone a “NORMAL” New Year???

Here’s wishing everyone a “NORMAL” New Year???

The holiday season often brings with it a reflection of the past year. Its highs, its lows, the challenges that we may have encountered and our hopes for the impending new year. Here Allergy Advocacy Association co-founder Jon Terry reflects upon this past year and offers his best wishes for a “normal” new year.

Staff of Allergy Advocacy Association. And Warm Holiday Wishes

By Jon Terry
December 6th, 2021

Greetings. As the holiday season begins, I sincerely hope you and your families are healthy and safe.

“Mom? What is…NORMAL?”
“It’s just a setting on the clothes dryer, honey.”

Looking back upon 2021, here in New York State I kept hoping and praying for a return to "NORMAL." I mean “NORMAL” from my own very personal perspective; of course, everyone has their own point of view and certainly yours will be a lot different from mine. Day after day, however, I didn't see much of anything resembling "NORMAL" happening all around me.

Just like everyone else the pandemic has changed so many different parts of my life: 

Continue Reading

Breast Milk from Mennonite Moms on Farms May Better Protect Babies from Allergies

Allergies now appear to be prevalent in our society, but that wasn’t always the case. Until the beginning of the 20th century, having a food allergy was rare. What factors have contributed to this explosion and what can we learn to perhaps find ways to help protect people. A fascinating study, by Dr Kirsi Järvinen-Seppo, an associate professor at the Division of Pediatric Allergy and Immunology and the Center for Food Allergy of the University of Rochester and Antti E. Seppo PHD

University of Rochester Medical School; Research Associate Professor explore the farming life of Mennotie families in upstate New York. In this study the authors examine the potential allergy protection benefits of breast milk from Mennontite moms to their babies as compared to the breast milk from mothers in urban settings.

Breast Milk from Mennonite Moms on Farms May Better Protect Babies from Allergies

Kirsi Jarvinen-Seppo, MD
Kirsi Jarvinen-Seppo, MD
Dr. Antti E. Seppo, PhD
Antti E. Seppo, PhD

This article was originally published in Frontiers in Immunology October 2021.

Women from traditional farming communities, such as old order Mennonites, may pass protection against atopic diseases on to their infants through their milk

Published by the American Association for the Advancement of Science (AAAS)

Continue Reading

Shazhad Mustafa, MD: Advancing Pediatric Peanut Allergy Management

If you are the parent of a child with a peanut allergy, you understand the challenges of both educating your child and being vigilant in avoiding contact with peanuts, or products that include peanuts. Both the challenges and means to decrease peanut sensitivity were topics at a recent Annual Scientific Meeting meeting of the American College of Asthma, Allergy, and Immunology (ACAAI). Included were discussions of Palforzia, a treatment option intended to decrease sensitivity to peanuts over time in pediatric populations.

Syed Shahzad Mustafa, MD, the University of Rochester Medicine and Dentistry, spoke with HPCLive regarding some of the data presented at ACAAI, as well as what physicians and caregivers could do to aid in the adoption of Palforzia therapy.

Shazhad Mustafa, MD: Advancing Pediatric Peanut Allergy Management

November 11, 2021
Armand Butera

Dr. S. Shazad Mustafa speaks on new data related to peanut allergy and Palforzia therapy that were presented at the most recent ACAAI session.

Syed Mustafa, MD

This past weekend, Aimmune Therapeutics presented new data at the American College of Asthma, Allergy, and Immunology (ACAAI) Annual Scientific Meeting that detailed the burden of peanut allergy (PA) in affected patients, as well as real-world experiences with Palforzia, a treatment option intended to decrease sensitivity to peanuts over time in pediatric populations.

Continue Reading

Study Finds Epinephrine Remains Alarmingly Underused for Anaphylaxis in Children

Cases of anaphylaxis in children are on the rise. And while there has been an increase in cases, the use of epinephrine “the treatment of choice for anaphylaxis and the only drug known to halt its progression — remains at suboptimal levels”. These were the findings of a recent study presented by  Dr Juli Wang, at the annual conference of the American College of Allergy, Asthma and Immunology (ACAAI). The report stated that “delayed administration of epinephrine has been linked to greater risk of a biphasic reaction, a reoccurrence of anaphylaxis that can happen hours after the initial symptoms are treated”. Dr. Wang is an MD and professor of pediatrics at the Icahn School of Medicine at Mount Sinai.

Viatris Epi-Pen

Study Finds Epinephrine Remains Alarmingly Underused for Anaphylaxis in Children

text

By Dave Bloom
2021/11/08

Dr Juli Wang, started her presentation of key updates in pediatric anaphylaxis at the annual conference of the American College of Allergy, Asthma and Immunology (ACAAI) with a warning:

Anaphylaxis remains an important allergic disorder, and the prevalence has been rising.

Dr Wang is an MD and professor of pediatrics at the Icahn School of Medicine at Mount Sinai, and the substance of her talk provided ample evidence.

According to data derived from the National Inpatient Sample on 2006 to 2015 cases of anaphylaxis, the prevalence has risen across most age groups — 3 to younger than 6 years, 6 to younger than 12 years, and 12 to younger than 18 years — with the highest increases seen in preschool- and elementary-aged children. Cases for children younger than 3 years remained steady.

Despite the rise in incidence, the use of epinephrine — the treatment of choice for anaphylaxis and the only drug known to halt its progression — remains at suboptimal levels.

Data from 20 studies show that following anaphylaxis from any cause, epinephrine was administered in as little as 1.4% of instances that subsequently required response from emergency medical services personnel and hospitalization.

Although another analysis of five US studies indicated a higher rate of 26.4%, the better rate still means “that only a quarter of anaphylaxis cases showing up to the emergency department [ED] were treated with epinephrine before EMS attention,” according to Wang.

Continue Reading

The information provided on this site is in no way intended to be a substitute for medical advice,
diagnosis, or treatment with a licensed physician.
The Allergy Advocacy Association is a 501(c)(3) non-profit, tax-exempt organization.
Copyright 2020 © Allergy Advocacy Association, Inc. All rights reserved.  Terms & Conditions